Recent studies reported that the use of neutralizing antibodies targeting the PLAG domain of PDPN can inhibit platelet aggregation by blocking PDPN-CLEC2 interaction, resulting in the suppression of tumor growth and metastasis38, 39, whereas a non-neutralizing anti-PDPN antibody also has been successfully used to suppress tumor development and hematogenous lung metastasis via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)40. The gene discussed is PDPN; the disease is neoplasm.